Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
A Unique Gene Expression Panel to Identify Operationally Tolerant Liver Transplant Recipients
FY 2014-15
Summary
Liver transplantation comprises 23% of solid organ transplants performed yearly in Canada. This life saving intervention is the last resort for adult and paediatric patients with end-stage liver failure. Immunosuppressive medication is required to prevent rejection and subsequent loss of the transplanted organ (graft). However, long-term use of these drugs leads to an increased risk for cardiovascular disease, cancer, diabetes, kidney failure, and infection. It has been clinically observed that 20% of liver transplant recipients do not experience graft rejection when immunosuppression is removed, and are deemed "Operationally Tolerant". In mouse models of liver and cardiac tolerance, our lab has identified a unique gene expression pattern that is associated with organ tolerance. Such a biomarker panel would allow for personalized immunosuppression regimes, in which tolerant patients would be recognized and safely taken off immunosuppression. In this project, we will validate the use of our previously described gene expression pattern for detecting tolerance in humans. We hypothesize that a unique gene expression pattern will identify operationally tolerant patients and allow for the discontinuation of their immunosuppression. The ability to safely remove long-term immunosuppression signifies an important cost reduction opportunity for the Canadian healthcare system and a major improvement in the length and quality of life of organ transplant recipients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331352
Name
Rojas Luengas Vanessa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Unique Gene Expression Panel to Identify Operationally Tolerant Liver Transplant Recipients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Diagnostic Technology; Fibrinogen-Like Protein 2 (Fgl2); Flow Cytometry; Gene Expression; Immunosuppression; Liver; Multiplex Real Time Qpcr; T Regulatory Cells; Tolerance
Abstract
Liver transplantation comprises 23% of solid organ transplants performed yearly in Canada. This life saving intervention is the last resort for adult and paediatric patients with end-stage liver failure. Immunosuppressive medication is required to prevent rejection and subsequent loss of the transplanted organ (graft). However, long-term use of these drugs leads to an increased risk for cardiovascular disease, cancer, diabetes, kidney failure, and infection. It has been clinically observed that 20% of liver transplant recipients do not experience graft rejection when immunosuppression is removed, and are deemed "Operationally Tolerant". In mouse models of liver and cardiac tolerance, our lab has identified a unique gene expression pattern that is associated with organ tolerance. Such a biomarker panel would allow for personalized immunosuppression regimes, in which tolerant patients would be recognized and safely taken off immunosuppression. In this project, we will validate the use of our previously described gene expression pattern for detecting tolerance in humans. We hypothesize that a unique gene expression pattern will identify operationally tolerant patients and allow for the discontinuation of their immunosuppression. The ability to safely remove long-term immunosuppression signifies an important cost reduction opportunity for the Canadian healthcare system and a major improvement in the length and quality of life of organ transplant recipients.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rojas Luengas, Vanessa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~